Last edition
News about
LG AI Research Partners with D&D Pharmatech for Oral Peptide Drug Discovery
LG AI Research and D&D Pharmatech have partnered to accelerate next-generation oral peptide drug discovery using advanced AI technologies. The collaboration aims to enhance drug development efficiency and strengthen LG’s leadership in the rapidly growing AI-driven biopharmaceutical market.
US FDA Expands OTC Access to Naloxone Nasal Spray for Opioid Overdose
US FDA expands Over-the-Counter (OTC) access to naloxone nasal spray for opioid overdose, supporting efforts to prevent overdose deaths and strengthen addiction recovery initiatives under the US government’s public health strategy.
Lupin Launches Azilsartan Medoxomil Tablets in US
Lupin has launched Azilsartan Medoxomil Tablets in the US, a bioequivalent generic version of Edarbi, indicated for the treatment of hypertension in adults.
J&J Commits Over USD 1 Billion to Expand US Vision Manufacturing
Johnson & Johnson is investing over USD 1 billion to expand its US Vision manufacturing operations in Jacksonville, Florida, adding advanced production, packaging, and distribution capabilities. The investment supports supply chain resilience, and is part of the company’s USD 55 billion US manufacturing and R&D commitment through 2029.
Vedana Therapeutics Launches with USD 46 Million Series A Financing for Migraine Therapies
Vedana Therapeutics has launched with USD 46 million in Series A financing to advance next-generation migraine therapies. Backed by migraine experts and investors, the company is developing innovative treatments targeting clinically validated pathways to help patients achieve lasting freedom from migraine.
Suven Life Sciences reported positive phase 2b results for Ropanicant in Major Depressive Disorder (MDD), achieving significant improvements in depression symptoms versus placebo. The treatment showed favorable safety and tolerability, with no withdrawal symptoms or dissociation, supporting advancement into a global phase 3 study.
Glenmark USA Launches Methylene Blue Injection USP 50 mg/10 mL
Glenmark Pharmaceuticals has launched Methylene Blue Injection USP 50 mg/10 mL, a bioequivalent and therapeutically equivalent generic version of ProvayBlue.
AviadoBio Broadens vMiX Platform Agreement with King's College London
AviadoBio has expanded its exclusive vMiX Precision Gene Silencing Platform agreement with King’s College London to cover all human therapeutic areas. Backed by positive AVB-406 preclinical data, the RNAi-based platform highlights broad potential for targeted gene therapies.
Zai Lab Secures EMA Orphan Drug Status for Zoci in Pulmonary Neuroendocrine Carcinomas
Zai Lab has received EMA Orphan Drug Designation (ODD) for zocilurtatug pelitecan (zoci) in pulmonary neuroendocrine carcinomas. The designation recognises promising clinical data suggesting potential benefits over existing therapies for patients with relapsed or refractory extensive-stage Small Cell Lung Cancer (SCLC).
Saptalis Launches Cyclosporine Ophthalmic Emulsion
Saptalis Pharmaceuticals has launched Cyclosporine Ophthalmic Emulsion 0.05 percent in 30- and 60-count single-use vials, expanding its ophthalmology portfolio and improving access to high-quality treatment options for patients.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy